What prices did the Guardant Health (GH) shares sell for in the Talasaz-related transactions?

The reported sales used weighted-average prices, with trades occurring in ranges from about $100.95 up to about $112.93 per share. Detailed trade-by-trade pricing within each range is available from the company or the SEC staff upon request.

Who executed the Guardant Health (GH) share sales reported for AmirAli Talasaz?

The sales were executed by the Talasaz and Eskandari 2017 Family Trust , which holds shares indirectly attributable to Co-CEO AmirAli Talasaz. All reported transactions involve common stock held through this trust, not directly in his individual name.

How many Guardant Health (GH) shares remain held after the Talasaz-related sales?

After the reported open-market sales, the Talasaz and Eskandari 2017 Family Trust held 2,096,304 shares of Guardant Health common stock. This figure reflects the indirect ownership position attributed to Co-CEO AmirAli Talasaz in the filing.

Were the Guardant Health (GH) sales by the Talasaz-related trust part of derivative exercises?

No. All reported transactions involve non-derivative common stock and are coded as open-market sales. The filing shows no derivative exercises, and the derivativeSummary section is empty, indicating no option or similar derivative activity in this report.

Guardant Health (GH) co-CEO’s family trust sells 210K shares of stock

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Guardant Health, Inc. disclosed that the Talasaz and Eskandari 2017 Family Trust, an entity associated with Co-Chief Executive Officer AmirAli Talasaz, completed a series of open-market sales of the company’s common stock.

The filing shows that the trust sold a total of 210,000 shares of Guardant Health common stock on May 20, 2026, across multiple trades. Reported weighted-average sale prices ranged from about $100.95 to about $112.76 per share, with detailed trade-by-trade pricing available on request from the company or the SEC staff. Following these transactions, the trust held 2,096,304 shares of Guardant Health common stock indirectly attributable to Talasaz.

Insights

Co-CEO-related trust sells 210,000 Guardant Health shares but retains a large position.

The filing shows the Talasaz and Eskandari 2017 Family Trust, associated with Co-CEO AmirAli Talasaz, executed open-market sales totaling 210,000 shares of Guardant Health common stock on May 20, 2026. Sale prices, reported as weighted averages, span roughly $100.95 to $112.76 per share.

These are discretionary open-market sales, which carry more informational weight than routine tax withholdings or option exercises. However, the trust’s post-transaction stake remains sizable at 2,096,304 shares, indicating that a substantial indirect ownership interest is still in place.

Overall, this looks like a notable but not transformational reduction in holdings tied to the co-CEO. The filing does not reference option exercises, derivative positions, or trading plans, so future company disclosures would be the place to look for additional context around Talasaz’s longer-term equity exposure.

Insider Trade Summary 10b5-1

Net Seller: 210,000 shares ($23,076,690)

Net Sell 12 txns

Insider Talasaz AmirAli

Role Co-Chief Executive Officer

Sold 210,000 shs ($23.08M)

Type	Security	Shares	Price	Value
Sale	Common Stock	200	$100.95	$20K
Sale	Common Stock	900	$102.57	$92K
Sale	Common Stock	1,366	$103.8178	$142K
Sale	Common Stock	11,919	$105.0079	$1.25M
Sale	Common Stock	1,200	$105.875	$127K
Sale	Common Stock	21,171	$106.9919	$2.27M
Sale	Common Stock	33,069	$108.1061	$3.57M
Sale	Common Stock	9,852	$108.9674	$1.07M
Sale	Common Stock	28,908	$110.0959	$3.18M
Sale	Common Stock	37,163	$111.1447	$4.13M
Sale	Common Stock	37,900	$112.0197	$4.25M
Sale	Common Stock	26,352	$112.7592	$2.97M

Holdings After Transaction: Common Stock — 2,096,304 shares (Indirect, Shares held by Talasaz and Eskandari 2017 Family Trust)

Footnotes (1)

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.29 to $103.06. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.40 to $104.26. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.400 to $105.39. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.49 to $106.42. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.57 to $107.52. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.59 to $108.57. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $108.59 to $109.56. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.66 to $110.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.72 to $111.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.70. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.74 to $112.93. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 210,000 shares Lowest weighted-average sale price range: $100.95/share Highest weighted-average sale price range: $112.93/share +2 more

5 metrics

Shares sold 210,000 shares Total common shares sold on May 20, 2026

Lowest weighted-average sale price range $100.95/share Approximate low end of reported sale-price ranges

Highest weighted-average sale price range $112.93/share High end of reported price ranges in footnotes

Shares held after transactions 2,096,304 shares Indirectly held by Talasaz and Eskandari 2017 Family Trust after sales

Number of sale transactions 12 transactions Non-derivative open-market sales on May 20, 2026

Key Terms

open-market sale, weighted average sales price per share, indirect ownership, non-derivative, +1 more

5 terms

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"ownership_type: indirect; nature_of_ownership: Shares held by Talasaz and Eskandari 2017 Family Trust"

non-derivative financial

"transaction_type: non-derivative"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 04:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Talasaz AmirAli

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/20/2026		S		200	D	$100.95	2,096,304	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		900	D	$102.57⁽¹⁾	2,095,404	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		1,366	D	$103.8178⁽²⁾	2,094,038	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		11,919	D	$105.0079⁽³⁾	2,082,119	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		1,200	D	$105.875⁽⁴⁾	2,080,919	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		21,171	D	$106.9919⁽⁵⁾	2,059,748	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		33,069	D	$108.1061⁽⁶⁾	2,026,679	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		9,852	D	$108.9674⁽⁷⁾	2,016,827	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		28,908	D	$110.0959⁽⁸⁾	1,987,919	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		37,163	D	$111.1447⁽⁹⁾	1,950,756	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		37,900	D	$112.0197⁽¹⁰⁾	1,912,856	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	05/20/2026		S		26,352	D	$112.7592⁽¹¹⁾	1,886,504	I	Shares held by Talasaz and Eskandari 2017 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.29 to $103.06. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.40 to $104.26. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.400 to $105.39. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.49 to $106.42. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

5. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.57 to $107.52. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

6. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.59 to $108.57. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

7. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $108.59 to $109.56. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

8. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.66 to $110.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

9. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.72 to $111.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

10. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.70. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

11. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.74 to $112.93. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How many Guardant Health (GH) shares were sold in this Form 4?

The Form 4 reports that a family trust associated with Co-CEO AmirAli Talasaz sold 210,000 shares of Guardant Health common stock. These were executed as multiple open-market sales on May 20, 2026, according to the transaction summary.